We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Proton Therapy for Early Stage Breast Cancer Less Expensive Than Various Alternative Radiotherapy Techniques

By MedImaging International staff writers
Posted on 11 Nov 2014
Print article
Patients with early stage breast cancer may benefit from accelerated partial breast irradiation (APBI) using proton therapy versus whole breast irradiation (WBI), in terms of duration of treatment and cost.

In a cost analysis study based on typical patient characteristics, researchers used Medicare reimbursement codes to analyze allowable charges for eight different types of partial and whole breast irradiation therapies and treatment schedules available to early stage breast cancer patients. Combined, these represent approximately 98% of the treatment alternatives available to these patients. The cost of proton therapy when used for APBI, introduced to decrease overall treatment time and toxicity, was estimated at USD 13,833. Comparatively, WBI using intensity-modulated radiation therapy (IMRT) resulted in the highest US Medicare charges at USD 19,599. The average charges across the eight treatment regimens were USD 12,784; thus, proton costs were similar to that of other types of radiation.

The findings were presented at the inaugural North America meeting of the Particle Therapy Cooperative Group (PTCOG) recently held at MD Anderson Proton Therapy Center (Houston, TX, USA). “It is often suggested that trials of proton APBI are irrelevant due to the modality's presumed high cost, but our data shows that this perception is false. Correcting this perpetual assumption is an important step in helping patients obtain the necessary health coverage to participate in clinical research,” said Valentina Ovalle, MD, postdoctoral research fellow and lead investigator. “Further, we anticipate that because charges vary proportionately across payers, the estimated Medicare reimbursement costs likely reflect relative charges to other third-party payers.”

Early breast cancer stage I or II is the most common invasive breast cancer in the US. With treatment, these patients generally have a good prognosis. Standard treatment approaches typically include breast-conserving surgery (BCS) followed by radiotherapy for the entire breast—five days per week, for up to six weeks, including one week of “boost” radiation to the area where the initial tumor was removed.

The role of APBI for early stage breast cancer is still being evaluated, but its intent is to deliver a highly effective dose of radiation while greatly reducing treatment time—10 treatments twice per day over one week. Furthermore, on average it spares at least two-thirds of breast tissue from a full dose of radiation. “The biggest drawback to WBI is that it is inconvenient, interrupting lives,” said Eric A. Strom, MD, FACR, study coauthor and professor in radiation oncology. Dr. Strom is lead investigator of a clinical trial sponsored by the US National Cancer Institute on proton APBI.

APBI is delivered via two approaches: brachytherapy and external beam. Proton therapy is offered as a type of external beam APBI, and according to Dr. Strom, is distinctive in its ability to provide the full dose of radiation precisely to the tumor site and nowhere else, eliminating radiation to the remaining breast, lung, and heart. To date, research on proton APBI has shown effective tumor control, limited side effects, and good cosmetic outcomes.

“This cost analysis must be interpreted in light of clinical evidence for proton APBI, which while still in nascent stages, is promising,” said Dr. Ovalle. “The findings counter the presumption that proton APBI is so expensive that even excellent clinical results would be immaterial. If the payment barrier for proton therapy is removed so that current and future research can proceed, the outcomes may ultimately benefit patients, physicians and insurers: better treatments at lower costs.”

Related Links:

MD Anderson Proton Therapy Center


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Dose Calibration Electrometer
PC Electrometer
New
Color Doppler Ultrasound System
DRE Crystal 4PX
New
Computed Tomography (CT) Scanner
Aquilion Serve SP

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.